Skip to main content

Breadcrumb

  1. Home

Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 18:36
  • Read more about Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 18:36
  • Read more about An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 18:36
  • Read more about Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

A Randomized Trial of NSAID Dosing Strategies

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 18:36
  • Read more about A Randomized Trial of NSAID Dosing Strategies

Telehealth CBT for Adolescents and Young Adults With Childhood-onset Systemic Lupus Erythematosus

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 18:36
  • Read more about Telehealth CBT for Adolescents and Young Adults With Childhood-onset Systemic Lupus Erythematosus

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008)

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 18:36
  • Read more about Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008)

PerQseal®+ Early Feasibility Study

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 18:36
  • Read more about PerQseal®+ Early Feasibility Study

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 18:36
  • Read more about A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 18:36
  • Read more about Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 18:36
  • Read more about Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 57
  • Page 58
  • Page 59
  • Page 60
  • Page 61
  • Page 62
  • Page 63
  • Page 64
  • Page 65
  • …
  • Next page Next
  • Last page Last
Subscribe to